Cytokinetics (FRA:KK3A) Additional Paid-In Capital : €1,703.98 Mil(As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics Additional Paid-In Capital?

Cytokinetics's quarterly additional paid-in capital increased from Sep. 2023 (€1,440.47 Mil) to Dec. 2023 (€1,582.58 Mil) and increased from Dec. 2023 (€1,582.58 Mil) to Mar. 2024 (€1,703.98 Mil).

Cytokinetics's annual additional paid-in capital increased from Dec. 2021 (€1,285.26 Mil) to Dec. 2022 (€1,398.62 Mil) and increased from Dec. 2022 (€1,398.62 Mil) to Dec. 2023 (€1,582.58 Mil).

Cytokinetics Additional Paid-In Capital Historical Data

The historical data trend for Cytokinetics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cytokinetics Additional Paid-In Capital Chart

Cytokinetics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

768.01

908.70

1,285.26

1,398.62

1,582.58

Cytokinetics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															1,391.49	1,397.58	1,440.47	1,582.58	1,703.98

Cytokinetics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Cytokinetics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Cytokinetics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cytokinetics (FRA:KK3A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (FRA:KK3A) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

CYTK:USA

Address

350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080

Website

https://www.cytokinetics.com

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics (FRA:KK3A) Headlines

No Headlines